化合物 AKT inhibitor VIII|T3346|TargetMol

AKT inhibitor VIII
612847-09-3

￥397 1mg 起订

￥587 2mg 起订

￥987 5mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 AKT inhibitor VIII

英文名称：: AKT inhibitor VIII

CAS号：: 612847-09-3

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 98.77%

产品类别：: 抑制剂

货号：: T3346

Product Introduction

Bioactivity

Name	AKT inhibitor VIII
Description	AKT inhibitor VIII (AKTi-1/2) is a highly specific Akt1/2 inhibitor (IC50: 58/210 nM). The selectivity for Akt1 is higher about 36-fold than Akt3.
Cell Research	The cell growth inhibitory effect of AKTi-1/2 is studied using the 96 h sulforhodamine B assay (SRB). Drug concentrations that inhibited 50% of cell growth (IC50) are calculated for each compound in GraphPad Prism 6.0 using non-linear regression analysis and sigmoidal dose–response (variable slope) equation.(Only for Reference)
Kinase Assay	Kinase screen: Briefly, all assays (25.5 μl at 21°C for 30 min) are performed using a Biomek 2000 Laboratory Automation Workstation in a 96-well format. Reactions contains 5–20 mU purified kinase along with substrate peptide or protein and are initiated by the addition of 10 mM MgAcetate and 5, 20, or 50 μM ATP ([γ-33P]-ATP, 800 cpm/pmol).
In vitro	Akti-1/2 (50 mg/kg,i.p.)抑制小鼠肺中基底和IGF-刺激的Akt1/2磷酸化作用.
In vivo	在基于细胞的IPKA (C33A)试验中,AKT inhibitor VIII可抑制Akt1/2（IC50：305/2086 nM）。在MCF7,HT29和A2780细胞中,AKT inhibitor VIII可使caspase-3活性急剧增加从而诱导细胞凋亡。在肝细胞中,AKT inhibitor VIII可阻断胰岛素对PEPCK的调节,以及G6Pase表达和FOXO1活性。AKT inhibitor VIII通过阻断PKB还可使PAR-1-介导的血小板聚集显著增强。在HCC827,NCI-H522,NCI-1651和PC-9细胞中,AKT inhibitor VIII抑制细胞生长（IC50：4.7/7.25/9.5 μM）,AKT inhibitor VIII与gefitinib联用会增强对细胞生长和凋亡的抑制。
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 11 mg/mL (20 mM), Heating is recommended.
Keywords	PKB \| Inhibitor \| AKT inhibitor VIII \| Akt \| Apoptosis \| Protein kinase B \| inhibit
Inhibitors Related	Metronidazole \| 5-Fluorouracil \| Stavudine \| Tributyrin \| Dextran sulfate sodium salt (MW 4500-5500) \| Myricetin \| Sorafenib \| 2,3-Butanediol \| L-Ascorbic acid \| Acetylcysteine \| Sodium 4-phenylbutyrate \| Kaempferol
Related Compound Libraries	Inhibitor Library \| Bioactive Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Metabolism Compound Library \| Anti-Colorectal Cancer Compound Library \| Kinase Inhibitor Library \| Anti-Aging Compound Library \| Highly Selective Inhibitor Library \| Anti-Lung Cancer Compound Library \| Antioxidant Compound Library

AKTi-1/2|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务